<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01216995</url>
  </required_header>
  <id_info>
    <org_study_id>ADVANCE</org_study_id>
    <nct_id>NCT01216995</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Adipose Derived Regenerative Cells (ADRCs) Delivered Via the Intracoronary Route in the Treatment of Patients With ST-elevation Acute Myocardial Infarction (AMI)</brief_title>
  <acronym>ADVANCE</acronym>
  <official_title>A Phase II Trial of Safety and Efficacy of ADRCs Delivered Via the Intracoronary Route in the Treatment of Patients With ST-elevation Acute Myocardial Infarction - The ADVANCE Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cytori Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cytori Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double blind, prospective, randomized, placebo-controlled Safety and Efficacy trial of ADRCs
      delivered via the intracoronary route in the treatment of patients with ST-elevation acute
      myocardial infarction (STEMI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, two arm, placebo-controlled, double blind, study that will
      enroll approximately 216 patients at no more than thirty-five (35) international clinical
      sites. Additional blinding measures will be taken in the assessment of study outcomes. The
      dose of the test material (ADRCs)is described in the protocol. The study will include two
      arms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Infarct Size</measure>
    <time_frame>6 Months</time_frame>
    <description>Reduction in infarct size at 6 months as measured by cardiac MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACCE Rates</measure>
    <time_frame>Through 36 months</time_frame>
    <description>Major Adverse Cardiac and Cerebral events (MACCE) is a composite clinical endpoint</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Dose A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dose A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dose A</intervention_name>
    <description>ADRC Dose A</description>
    <arm_group_label>Dose A</arm_group_label>
    <other_name>Adipose-Derived Regenerative Cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Comparator</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  ST-segment Elevation Myocardial Infarction (STEMI) Criteria:

          -  Ischemic symptoms AND

          -  ECG:

          -  Development of pathologic Q waves on the ECG; or

          -  ECG changes indicative of severe ischemia (ST segment elevation and/or depression); or

          -  New left bundle branch block; AND

          -  Creatine Phosphokinase Isoenzyme (MB Form) &gt; 100 IU/L, or troponin &gt;5x the upper limit
             of normal between admission and randomization

          -  Successful revascularization of the culprit lesion in a major epicardial vessel

        Key Exclusion Criteria:

          -  More than 24 hours between PCI and start of liposuction

          -  Prior myocardial infarction, cardiomyopathy, or a history of congestive heart failure

          -  Pacemaker, ICD, or any other contra-indication for MRI

          -  Patients with increased bleeding risk

          -  Cardiogenic shock present post-index PCI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Kesten, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cytori Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Erasmus University Medical Centrum</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krakowski Szpital Specjalistyczny im. Jana Pawla II Oddzial Kliniczny Chorob Serca i Naczyn</name>
      <address>
        <city>Krakow</city>
        <zip>31202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki Samodzielna Pracownia Zakladu Hemodynamiki</name>
      <address>
        <city>Krakow</city>
        <zip>31501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Centralny Szpital Kliniczny Pracownia Kardiologii Inwazyjnej</name>
      <address>
        <city>Warsaw</city>
        <zip>02097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2010</study_first_submitted>
  <study_first_submitted_qc>October 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2010</study_first_posted>
  <last_update_submitted>November 19, 2014</last_update_submitted>
  <last_update_submitted_qc>November 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Attack</keyword>
  <keyword>Regenerative Cells</keyword>
  <keyword>Stem Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

